About the Editors

Editor-in-Chief

Larry Norton, MD
Medical Director
Evelyn H. Lauder Breast Center
NY, USA


Dr. Larry Norton is a board-certified medical oncologist with broad interests in cancer prevention, diagnosis and treatment. His research concerns the basic biology of cancer, the mathematics of tumor causation and growth and the development of approaches to better diagnosis, prevention and drug treatment of the disease. He is involved in many areas of research including identifying the genes that predispose people to cancer or that cause cancer, developing new drugs, monoclonal antibodies that target growth factor receptors and vaccines. A major milestone in his research career was the development of an approach to therapy called "dose density," or "sequential dose density."

Deputy Editors

Sunil S Badve, MD
Prof. and Vice Chair, Dept. of Pathology and Lab Medicine
Emory University
Atlanta,
GA, USA

Sunil Badve, M.D., FRCPath, is the Vice Chair, and Director of the Pathology Cancer Program at Emory University. He is a surgical pathologist and a translational researcher in breast cancer for over 20 years. Dr. Badve has been recognized by the Scholar Award from Susan G. Komen for the Cure (2010-2018 and Current 2022-2025) as Best Doctor and has received the AACR Team Sciences Award (2020) as a member of the TCGA Team. Dr. Badve has served on several committees including – the (NCI) Breast Oncology Local Disease, the ECOG Breast Committees, the AJCC (8th edition) and WHO for breast and thymic cancers. Dr. Badve currently serves on the NCI Breast Cancer Steering Committee, and have served on the Breast Cancer Correlative Sciences Committee, and the ASCO-CAP committee to develop guidelines for hormone receptor testing.  

Zoltan Szallasi, MD
Asst. Prof. of Pediatrics
Harvard Medical School
MA, USA


Zoltan Szallasi, MD is a senior research scientist in the Computational Health Informatics Program, at Children’s Hospital, Boston, Harvard Medical School. Dr. Szallasi's group has been applying genomics to characterize key cancer associated biological processes. His main work is focusing around detecting and quantifying DNA repair deficiencies in breast cancer and other solid tumors using next generation sequencing data. The main goal of this work is to enable synthetic lethality driven cancer therapies that target aberrations in specific DNA repair pathways such as homologous recombination or nucleotide excision repair.

Sarat Chandarlapaty, MD, PhD
Member, Human Oncology and Pathogenesis Program
Memorial Sloan Kettering,
New York, NY USA

 

Dr. Sarat Chandarlapaty is a Member and Laboratory Head in the Human Oncology and Pathogenesis Program and the Breast Cancer Medicine Service at Memorial Sloan Kettering. The goal of Dr. Chandarlapaty’s research is to investigate the mechanisms and consequences of activation of growth factor and hormonal signaling pathways in breast cancer and translate those findings towards the development of more effective and durable treatments for metastatic disease. A major focus of his laboratory has been to characterize the significance of alterations present in breast tumors that have progressed on targeted therapy and devise therapeutic strategies that can overcome these forms of drug resistance.

Managing Editor

Aparna Anantharaman, PhD 

Aparna earned her PhD in bioscience from New Delhi, India where she designed and tested antibiotic peptides against pathogenic bacteria. She then moved to the US to work as a postdoctoral researcher and gained over nine years of research experience in gene regulation and RNA biology. Aparna has expertise in advanced molecular and cellular biology, biochemistry, biophysics, and basic bioinformatics. She transitioned into publishing in 2023 and now serves as a Managing Editor for the npj Series. She is based in the Philadelphia office.

Associate Editors

Prasanna Alluri, MD, PhD
Assistant Professor, Department of Radiation Oncology
UT Southwestern Medical Center
Dallas, TX


Prasanna Alluri, MD, PhD is a physician scientist specializing in the treatment of patients with breast cancer. Research in his laboratory is focused on studying mechanisms of treatment resistance in patients with breast cancer and developing novel targeted therapies to overcome such resistance. He also serves as a PI or co-PI on several innovative clinical trials in breast cancer.

Kim Blenman, PhD
Assistant Professor of Medicine (Medical Oncology) Yale School of Medicine and of Computer Science, Yale School of Engineering and Applied Science
Yale University
CT, USA

Dr Blenman’s interest is in clinical research, AI/ML software development, therapeutic development, and health disparities. Her disease focus areas are cancer and autoimmunity with a special interest in the therapy-induced toxicity (treatment emergent adverse events (TEAEs)) bridge between the two disease areas. Her research centers around developing prognostic and predictive tools for drug therapeutic efficacy and TEAEs.

Dr Neil M. IyengarNeil M. Iyengar, MD
Assistant Attending Physician, Breast Medicine Service/Department of Medicine
Memorial Sloan Kettering Cancer Center
NY, USA

Dr. Iyengar leads a research program focused on methods to improve cardiometabolic health as a strategy to reduce breast cancer risk and improve response to cancer therapy. His research also investigates the use of drugs that treat metabolic disorders, such as diabetes and obesity, to improve the effectiveness of cancer therapies. Dr. Iyengar leads the Optimal Living Program, a novel care model that aims to translate research findings from lifestyle intervention trials into clinical practice during and after cancer therapy.

Hiroji Iwata, MD, PhD
Specially Appointed Professor
Nagoya City University, Graduate School of Medical Sciences
Department of Advanced Clinical Research and Development
Nagoya, Japan

Dr. Iwata is the past director of Japanese Breast Cancer Society (JBCS) and Japanese Society of Medical Oncology (JSMO), 28th Congress President of JBCS annual meeting (2020) and 21th Congress president of JSMO annual meeting (2024). He has worked at the Aichi Cancer Centre for 26 years, treating breast cancer patients and developing new drugs in the field of breast cancer. In particular, he has been involved in the development of T-DXd, a revolutionary drug for the treatment of breast cancer, from the first in human trials and has made many achievements. He has authored over 300 publications on a wide range of subjects in the treatment of early stage and metastatic breast cancer. For the past 14 years, he has served as the director of Breast Cancer Study Group in Japan Clinical Oncology Group (JCOG) and a number of clinical trials that have been initiated, the results of which are highly anticipated. He has also been a steering committee member for many global clinical trials.

Caterina Marchio, PhD
Assoc. Prof. of Pathology
University Turin at Candiolo Cancer Institute - FPO IRCCS
Candiolo, Italy


Caterina Marchiò leads the Research Program of the Pathology Unit at the Candiolo Cancer Institute where her research interests span from histopathogenesis of breast carcinomas to molecular pathology of special histologic types of breast cancer and genetics of HER2-positive and HER2-low carcinomas. She is actively involved in the standardization of preanalytical conditions in Pathology to ensure optimal tissue preservation and quality of DNA, RNA and antigens to guarantee the success of precision medicine.

Aleix Prat Aparicio headshotAleix Prat Aparicio, MD, PhD
Director Instite Clinic Hematological and oncology issues - ICMHO
Hospital Clinic, IDIBAPS, University of Barcelona
Barcelona, Spain


My research is leading is based on using genomic data to guide the design of clinical trials and biomarker development in order to identify more optimal treatments for patients with cancer. Specifically, its main strategic lines are: Assist in implementing and developing genomic platforms applicable in daily clinical practice; Participate in prospective and retrospective studies where scientists genomics of tumors analyzed; Validation of predictive genomic biomarkers and / or forecasts in clinical trials and evaluate gene expression data as a tool to identify new mechanisms of sensitivity/drug resistance and/or new therapeutic targets as immunotherapy.

Andrea L RichardsonAndrea L. Richardson, MD, PhD
Assoc. Prof. of Pathology
Johns Hopkins Medicine
Baltimore, MD, USA


Andrea Richardson M.D. Ph.D. is Associate Professor and Director of Pathology for the Johns Hopkins Medicine National Capital Region where she is a practicing physician and translational breast cancer scientist. Her research has focused on characterizing the molecular aberrations in subtypes of breast cancer important for pathogenesis, tumor progression, and tumor response to therapy. Through genomic analysis of tissues, her laboratory identified a DNA damage signature termed NtAI that is high in BRCA-like cancers and predicts for response to certain drugs. Myriad has developed this predictor into a commercial test (MyChoice CDx) which is now available for clinical use. Her current research expands on these findings to study the role of mutational signatures in tumors and cell line models to predict for DNA damage repair defects and drug sensitivity.

Fernando SchmittFernando Schmitt, MD, PhD
Prof. of Pathology
Medical Faculty of Porto University
Porto, Portugal


Professor of Pathology at the University of Porto, Director of RISE (Clinical and Translational Research Network of the Medical Faculty) and Head of Molecular Pathology at IPATIMUP.Past-President of the International Society of Breast Pathology and General Secretary and President-elect of the International Academy of Cytology (IAC). He has authored more than 500 papers in peer-review journals, 33 book chapters and he is editor of 6 books. He is widely considered a world-leading expert in cytopathology and breast cancer. His research work is on breast cancer, with emphasis on molecular markers and therapeutic targets.

Priyanka Sharma, MD
Prof., Division of Medical Oncology
University of Kansas Medical Center
Westwood,
KS, USA

In addition to national and institutional leadership roles, Prof Sharma is very actively involved in clinical and translational breast cancer research. Her long-term research goal is to delineate personalized treatment strategies for triple-negative breast cancer (TNBC) and BRCA mutation-associated breast cancer. She serves as Translational PI of an ongoing NCI-funded SWOG trial for patients with TNBC (S1416) and as PI of an active translational SWOG study (S9313c) which also focuses on TNBC. Outside of SWOG Prof Sharma has served as PI of several investigator-initiated trials assessing novel therapeutic agents for breast cancer.

Dipali Sharma, PhD
Professor, Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Professor of Oncology, Johns Hopkins
Baltimore, MD, USA


Dr. Sharma’s laboratory focuses on elucidating the molecular mechanisms underlying breast cancer initiation and progression and developing various preventive and treatment strategies using mouse models and human samples. Areas of specific interest include understanding the molecular connections between breast cancer and obesity, racial disparities, and microbial dysbiosis.

Joseph A. Sparano, MD
Prof. of Medicine & Obstetrics, Gynecology and Women's Health
Albert Einstein College of Medicine
NY, USA


Joseph Sparano's research has focused on developmental therapeutic approaches for breast cancer, lymphoma and HIV-associated cancers, and therapeutic application of molecular profiling in cancer. Dr. Sparano serves as Vice Chair of the ECOG-ACRIN Research Group and Vice Chair of the AIDS Malignancy Consortium.

Jonas Teuwen,PhD
Group Leader AI for Oncology
Netherlands Cancer Institute
Amsterdam, Netherlands


Jonas Teuwen is the Group Leader of AI for Oncology at the Netherlands Cancer Institute in Amsterdam. As the group leader, he is responsible for leading the development of artificial intelligence innovations to improve cancer diagnostics and treatment. The AI for Oncology lab focuses on a wide range of research studies, from basic to translational, with a significant emphasis on breast cancer. Its work includes developing AI systems to support breast radiologists and creating predictive models for immune therapy response, showcasing a strong commitment to advancing patient care through AI.

Mangesh Thorat, MBBS, MS, FEBS, PhD
Honorary Reader,Wolfson Institute of Population Health, Queen Mary University of London​
London, UK



Mangesh Thorat is an oncoplastic breast surgeon based in London, United Kingdom and his research primarily focusses on cancer prevention. His cancer prevention research is underpinned by three main strands of work. The first of these is cancer epidemiology with a focus on drug repurposing, for example, Aspirin. The second strand involves early detection and prognostic biomarkers, with a special focus on DCIS. And the third strand is cancer prevention / early detection clinical trials, with a special focus on breast cancer prevention. He serves on steering committees of multiple international cancer prevention societies, multinational cancer prevention trials as well as on research funding committees of multiple cancer charities across Europe.

Founding Editor

Clifford A. Hudis, MD
Chief, Breast Cancer Medicine Service
Memorial Sloan Kettering Cancer Center
NY, USA
 

Cliff Hudis is a medical oncologist with research interests in all areas of care related to breast cancer. A particular research focus of his team is the interplay between inflammation, obesity and breast cancer, and they are now actively translating their findings into clinically relevant trials with the potential to reduce the global burden of breast and other cancers.


Advisory Editor

Stephanie Koo





Stephanie Koo is a senior editor of the Cancer Team in Nature Communications, where she handles manuscripts in the areas of cancer cell biology and cancer molecular biology. She received her PhD in cancer biology from National University of Singapore and completed two postdoctoral works that focused on kinase signalling, transcription factors, and breast cancer development. She is based in Springer Nature’s London office.

Editorial Board Members 

Kathy S. Albain, MD, FACP Loyola University Chicago, IL, USA
Sunil Badve, MD Indiana University School of Medicine, Indiana, USA
Gabor Balázsi, PhD Stony Brook University, New York, USA
John M.S. Bartlett, PhD Ontario Institute for Cancer Research Toronto, Ontario, Canada
Debra L. Barton, PhD University of Michigan, MI, USA
Powel H. Brown, MD University of Texas, MD Anderson Cancer Center Houston, Texas, USA
Maggie Cheang, MD The Institute of Cancer Research Surrey, London, UK
Lewis A. Chodosh, MD University of Pennsylvania, Pennsylvania, USA
Carsten Denkert, MD, PhD Charité Universitätsmedizin Berlin, Berlin, Germany
Matthew J. Ellis, BSc, MB, BChir, PhD, FRCP Baylor College of Medicine, Texas, USA
Prudence A. Francis, MD Peter MacCallum Cancer Centre, Melbourne, Australia
Benita S. Katzenellenbogen, MD University of Illinois Urbana-Champaign, Illinois, USA
Seema A. Khan, MD Northwestern University Evanston, Illinois, USA
Ian E. Krop, MD, PhD Dana-Farber Cancer Institute/Harvard Medical School, MA, USA
Adrian V. Lee, PhD University of Pittsburgh, Pennsylvania, USA
Ephrat Levy-Lahad, MD Shaare Zedek Medical Center, Jerusalem, Israel
Sherene Loi, MD, PhD University of Melbourne, Melbourne, Australia
Caterina Marchio, PhD University of Turin, Turin, Italy
Stefan Michiels, PhD Université Paris-Sud Paris, Paris, France
Harikrishna Nakshatri, PhD, Indiana University School of Medicine, USA
Kenneth Offit, MD, MPH Memorial Sloan Kettering Cancer Center, New York, USA
Edith A. Perez, MD Mayo Clinic Jacksonville, Florida, USA
Stuart J. Schnitt, MD Brigham and Women's Hospital, Massachusetts, USA
Dipali Sharma, PhD Professor of Oncology, Johns Hopkins, USA
Valerie Speirs, PhD Leeds Institute of Cancer & Pathology, Leeds, United Kingdom
Anne Vincent-Salomon, PhD Institut Curie Paris, Paris, France
Geoffrey M. Wahl, MD Salk Institute La Jolla, California, USA
Jedd Wolchok, MD, PhD Memorial Sloan Kettering Cancer Center, New York, USA

 

Interested in joining the journal team?

If you are interested in joining the journal as an Editorial Board Member or Associate Editor, please complete this Google form. Associate Editors are part of the editorial team that handle manuscripts, while Editorial Board Members are regular reviewers and are consulted for ad hoc advice. We will contact you if your expertise meets the needs of the journal.

Nature Portfolio journals are committed to promoting practices that support diversity, equity and inclusion in science communication and publishing, and we strongly encourage gender, race, ethnic, geographic, career stage and other diversity in our journal teams. Our in-house staff will use your information only for the purposes of identifying new editorial team or board members. Please contact the journal by email if you would like to remove your information from these records.

Please note that we are not able to respond to all applicants.